DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Sponsor: Roswell Park Cancer Institute
This PHASE1 trial investigates Acute Myeloid Leukemia and Alkylating Agent-Related Acute Myeloid Leukemia and is currently completed. Roswell Park Cancer Institute leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jan 2020 — Feb 2020 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2020 [monthly]
Completed PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Roswell Park Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .